Market Overview

The Global Biopharmaceutical Contract Manufacturing Market was valued at USD 41,718.1 million in 2023 and is expected to reach USD 116,522.1 million by 2031 while growing at a CAGR of 13.7% during the forecast period (2024-2031). 

 *Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Market Dynamics

This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global biopharmaceutical contract manufacturing market growth. Biopharmaceutical contract manufacturing involves outsourcing the production of therapeutic drugs derived from biological sources to specialized third-party organizations, known as contract manufacturing organizations (CMOs) or contract development and manufacturing organizations (CDMOs). These drugs include monoclonal antibodies, vaccines, gene therapies, and recombinant proteins.

The rising prevalence of chronic diseases and an aging population, coupled with cost efficiency, flexibility, and ongoing advancements in bioprocessing technologies, are expected to significantly boost the Biomaterials market. Despite this potential growth, challenges such as stringent regulatory requirements, compliance standards, and issues related to quality control and assurance may hinder the market's expansion.

Furthermore, the global biopharmaceutical contract manufacturing industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.

Segmentation – By Product Type Analysis

The Global Biopharmaceutical Contract Manufacturing Market is segmented among Peptides/Proteins, Antibodies, Vaccines, Biosimilars, and Other Product Types, based on Product Type. In 2023, Vaccines accounted for the majority of the market share*. 

 *Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Global Biopharmaceutical Contract Manufacturing Market: Regional Analysis

Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Asia Pacific is expected to grow with the highest CAGR during the forecast period (2024 – 2031). 

 *Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Competitive Landscape

Some of the key players operating in the market are Boehringer Ingelheim GmbH, Lonza Group, Inno Biologics Sdn Bhd, Rentschler Biotechnologie GmbH, JRS Pharma (Celonic), Samsung BioLogics, WuXi Biologics, AGC Biologics, ProBioGen AG, and FUJIFILM Diosynth Biotechnologies USA Inc

Table of Contents:

1. Research Methodology and Market Scope

• Research Methodology

• Market Scope

2. Executive Summary

3. Global Biopharmaceutical Contract Manufacturing Market Dynamics

• Drivers

• Restraints

• Opportunity

4. Global Biopharmaceutical Contract Manufacturing Industry Analysis

• PEST Analysis

• Porter's Five Force Analysis

• Recent Deals Analysis

5. Global Biopharmaceutical Contract Manufacturing Market Segmentation, By Product Type

• Global Biopharmaceutical Contract Manufacturing Market Share Analysis, By Product Type

• Global Biopharmaceutical Contract Manufacturing Market Growth Analysis, By Product Type

• Global Biopharmaceutical Contract Manufacturing Market Trends, By Product Type

o Peptides/Proteins

o Antibodies

o Vaccines

o Biosimilars

o Other Product Types

6. Global Biopharmaceutical Contract Manufacturing Market Segmentation, By Region

• Global Biopharmaceutical Contract Manufacturing Market Share Analysis, By Region

• Global Biopharmaceutical Contract Manufacturing Market Growth Analysis, By Region

• Global Biopharmaceutical Contract Manufacturing Market Trends, By Region

o North America

o Europe

o Asia Pacific

o Latin America

o Middle East

o Africa

7. Competitive Landscape

• Boehringer Ingelheim GmbH*

o Company Overview

o Financial Performance

o Key Development/Strategies

o SWOT Analysis

• Lonza Group

• Inno Biologics Sdn Bhd

• Rentschler Biotechnologie GmbH

• JRS Pharma (Celonic)

• Samsung BioLogics

• WuXi Biologics

• AGC Biologics

• ProBioGen AG

• FUJIFILM Diosynth Biotechnologies USA Inc 

*Similar analysis will be provided for each company listed above.